Therapeutic product registration could be jeopardised by omitting to disclose a pertinent patent, regardless of whether the omission was wilful

Pursuant to the Health Products (Therapeutic Products) Regulations ("HPR"), applicants for registration of a therapeutic product with the Health Sciences Authority ("HSA") in Singapore must declare whether "a patent is in force in respect of the therapeutic product" ("pertinent patent"). This requirement is part of the patent linkage system in Singapore, which ensures that no therapeutic product would be approved before the expiration of the pertinent patent, except with the consent of the owner of the pertinent patent.

In the recent decision of Millennium Pharmaceuticals, Inc, vs Zyfas Medical Co [2020] SGHC 28, the High Court granted a declaration that Zyfas had omitted to disclose matter that is material to its application for the registration of a therapeutic product, even though Zyfas'…

Full article available on PatentHub

Latest insights

More Insights
Birds on a beach

China Cybersecurity and Data Protection: Monthly Update - April 2024 Issue

Apr 26 2024

Read More
Curiosity line yellow background

Bring out the wine and cheese: Enhanced protection for European GIs in New Zealand

Apr 26 2024

Read More
Green paper windmill

Green Gold: Navigating Mandatory Climate Disclosure and ESG Strategies

Apr 26 2024

Read More